Pharmacoeconomics and Health Outcomes Research Iberia

Pharmacoeconomics and Health Outcomes Research Iberia is a Spain-based company headquartered in Madrid. As its name indicates, the firm operates in the specialised field of pharmacoeconomics and health outcomes research — an area of health economics that evaluates the cost, effectiveness and real-world impact of medicines and health technologies. Such work is typically used by pharmaceutical manufacturers, healthcare payers, hospitals and public health authorities to support pricing, reimbursement and market-access decisions. The company is associated with the Iberian market, meaning Spain and Portugal, and its web presence is hosted at porib.com. Publicly available structured data identifies it simply as a company in Madrid, Spain, without further detail on ownership, founding date or executive leadership. It should therefore be understood as a specialised professional-services provider rather than a large pharmaceutical manufacturer or a retail pharmacy chain. Because the firm is small and privately held, detailed financial and corporate information is not widely published. Its relevance lies in the niche expertise it represents: the intersection of clinical evidence, economic modelling and health-policy decision-making in Southern Europe.

Pharmacoeconomics and Health Outcomes Research Iberia is documented in public structured data as a company located in Madrid, Spain. The available evidence does not record a founding date, founder, ownership structure or corporate history. Its name and web presence indicate that it was established to provide pharmacoeconomics and health outcomes research services to clients in the Iberian Peninsula. The field in which the firm operates emerged as a distinct discipline from the 1980s and 1990s onward, as health systems increasingly required economic evidence to justify the pricing and reimbursement of medicines. In Spain, the growth of health technology assessment and regional reimbursement processes created demand for specialised consultancies capable of producing cost-effectiveness analyses, budget-impact models and real-world evidence studies. Firms such as this one position themselves between pharmaceutical companies and public payers, translating clinical trial data into economic arguments relevant to local decision-makers. No verified information is available on mergers, acquisitions, leadership changes or expansions. The company appears to remain a small, privately held professional-services provider focused on its home market.

Specialist consultancy in pharmacoeconomics and health outcomes research serving the Iberian healthcare market.

• Pharmacoeconomic evaluations

  Economic analyses of medicines and health technologies, including cost-effectiveness and cost-utility studies.

• Health outcomes research

  Studies measuring clinical, humanistic and economic outcomes of healthcare interventions.

• Budget-impact and market-access support

  Modelling and evidence support for pricing and reimbursement submissions.

1. 1Wikidata: Pharmacoeconomics and Health Outcomes Research Iberiawikidata.org
2. 2Pharmacoeconomics and Health Outcomes Research Iberia websiteporib.com